Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recordati SpAMIL:REC +0.19%96 Debt-to-EBITDA is 2.14 as of Mar. 2026, which is 9% above its 10-year median of 1.96. GuruFocus rates MIL:REC with a GF Score™ of 96/100 and a GF Value™ of €60.85 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 690 Drug Manufacturers companies, Recordati SpA ranks worse than 64.06% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Recordati SpA's Debt-to-EBITDA or its related term are showing as below:
MIL:REC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.95 Med: 1.96 Max: 3.12
Current: 2.57
During the past 13 years, the highest Debt-to-EBITDA Ratio of Recordati SpA was 3.12. The lowest was 0.95. And the median was 1.96.
MIL:REC's Debt-to-EBITDA is ranked worse than 64.06% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs MIL:REC: 2.57
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Recordati SpA Debt-to-EBITDA Related Terms
Recordati SpA Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Recordati SpA's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:REC vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Recordati SpA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Recordati SpA's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Recordati SpA (MIL:REC) has a Debt-to-EBITDA of 2.14 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Recordati SpA. This is near median its historical median of 1.96. Over the past decade, Recordati SpA's Debt-to-EBITDA has ranged from 0.95 to 3.12. According to the industry distribution chart, Recordati SpA ranks #442 out of 690 companies in the Drug Manufacturers industry, placing it in the top 64.1%.
Is Recordati SpA's Debt-to-EBITDA too high?
Recordati SpA's current Debt-to-EBITDA of 2.14 is near median its 10-year median of 1.96. Over the past 10 years, this metric has ranged from a low of 0.95 to a high of 3.12. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Recordati SpA's value of 2.14 is 27.4% above this industry median. Based on the distribution chart, Recordati SpA ranks #442 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Recordati SpA has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #442 out of 690 companies for Debt-to-EBITDA. This places Recordati SpA in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. Recordati SpA's value of 2.14 is 27.4% above this benchmark. Historically, Recordati SpA's own Debt-to-EBITDA has ranged from 0.95 to 3.12 over the past decade. While the company's 10-year median is 1.96 vs. the industry median of 1.68, Recordati SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current Debt-to-EBITDA of 2.14 is 27.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Recordati SpA. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current Debt-to-EBITDA is 2.14, which is near median its own 10-year median of 1.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €60.85, compared to a current price of €51.40 — trading 15.5% below its estimated fair value. The current Debt-to-EBITDA is 2.14, which is near median its 10-year median of 1.96 and 27.4% above the Drug Manufacturers industry median of 1.68. Recordati SpA's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current Debt-to-EBITDA is 2.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €51.40 is trading 15.5% below its estimated GF Value™ of €60.85.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
Debt-to-EBITDA: 2.14 (near median its 10-year median of 1.96)
GF Value™: €60.85 vs. price of €51.40 (15.5% below fair value)
Industry Position: 27.4% above the Drug Manufacturers median (#442 of 690)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
96GF Score
Get the complete analysis for MIL:REC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 
